Benutzer: Gast  Login
Titel:

Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial.

Dokumenttyp:
Article; Journal Article
Autor(en):
Hasan, Alkomiet; Roeh, Astrid; Leucht, Stefan; Langguth, Berthold; Hansbauer, Maximilian; Oviedo-Salcedo, Tatiana; Kirchner, Sophie K; Papazova, Irina; Löhrs, Lisa; Wagner, Elias; Maurus, Isabel; Strube, Wolfgang; Rossner, Moritz J; Wehr, Michael C; Bauer, Ingrid; Heres, Stephan; Leucht, Claudia; Kreuzer, Peter M; Zimmermann, Stephanie; Schneider-Axmann, Thomas; Görlitz, Thomas; Karch, Susanne; Egert-Schwender, Silvia; Schossow, Beate; Rothe, Philipp; Falkai, Peter
Abstract:
Background: Preclinical studies recently showed that the mineralocorticoid antagonist spironolactone acts also as an antagonist of the NRG1-ERBB4 signaling pathway and improves schizophrenia-like behaviour in Nrg1 transgenic mouse model. As this signaling pathway is critically linked to the pathophysiology of schizophrenia, especially in the context of working-memory dysfunction, spironolactone may be a novel treatment option for patients with schizophrenia targeting cognitive impairments. Aims:...     »
Zeitschriftentitel:
Contemp Clin Trials Commun
Jahr:
2020
Band / Volume:
17
Volltext / DOI:
doi:10.1016/j.conctc.2020.100537
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/32072071
TUM Einrichtung:
Klinik und Poliklinik für Psychiatrie und Psychotherapie; Kliniken und Institute
 BibTeX